Physician profile
Anna Deocampo
NPI 1295781193
$13,104.82
in general payments reported to CMS, 2019-2025
15 companies · $381 in 2025
The $381 reported for 2025 was more than what 82% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $79.62 · 2021: $617 · 2022: $7,894 · 2023: $2,288 · 2024: $1,050 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,680 · Food and Beverage: $1,549 · Consulting Fee: $480 · Education: $5.17 · Travel and Lodging: $4.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,680.00 |
| Food and Beverage | $1,548.78 |
| Consulting Fee | $480.00 |
| Education | $5.17 |
| Travel and Lodging | $4.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $10,059.05 | 2022-2025 | Azstarys, Azstarys |
| Tris Pharma INC | $843.15 | 2019-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $744.63 | 2021-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $369.41 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $339.71 | 2019-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $175.22 | 2025 | Jornay Pm |
| Biogen, INC. | $115.10 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $100.09 | 2019 | |
| Acorda Therapeutics, INC | $98.77 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.95 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $80.16 | 2019-2025 | Relexxii |
| Shire North American Group INC | $37.23 | 2019 | |
| Adlon Therapeutics L.P. | $18.73 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.73 | 2019 | |
| Merz North America, INC. | $15.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Deocampo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.